Under construction – not a live service
Sign in
Taking peoplePhase 1/2

Tests RAS(ON) inhibitors in lung cancer with RAS gene mutations

Tests new RAS(ON) inhibitor drugs in adults with advanced RAS-mutated lung cancer.

Key facts

Who runs it
Revolution Medicines, Inc.
Where
Kaohsiung City, Taichung, Tainan, and Taipei, TaiwanSee the 5 sitesAlso in 12 other countries, 86 sites
Registry title
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Status
Recruiting
Phase
Phase 1/2
People taking part
616 people, planned
Started
18 Jan 2024
Expected to end
Dec 2028
Type of study
Interventional, 4 groups
Treatments tested
  • RMC-6291
  • RMC-6236
  • Pembrolizumab
  • Cisplatin
  • Carboplatin
  • Pemetrexed
  • RMC-9805
Record updated
19 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced lung cancer (NSCLC) caused by a RAS gene change. It tests new RAS(ON) inhibitor drugs, alone or with standard treatment.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Locally advanced or metastatic cancer that cannot be cured by surgery. Subprotocol A: KRAS G12C-mutated solid tumor. Subprotocol B: RAS-mutated NSCLC. Subprotocols C and D: RAS G12D-mutated NSCLC.
Earlier treatment
People must have had standard therapy that fits their tumor type and stage.
Biomarker or test result
A documented RAS gene change: KRAS G12C (Subprotocol A), RAS mutation (Subprotocol B) or RAS G12D (Subprotocols C and D).

Main reasons for not taking part

  • Primary tumors of the brain or spinal cord (central nervous system)
  • Stomach or bowel problems that could change how the drugs are absorbed
  • Major surgery less than 28 days before the first dose
  • Current or past interstitial lung disease or pneumonitis that needed steroids

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • All Patients (unless otherwise noted):
  • ≥ 18 years of age
  • ECOG PS is 0 to 1
  • Adequate organ function as outlined by the study
  • Received prior standard therapy appropriate for tumor type and stage
  • Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)
  • Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)
  • Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)

Who cannot take part

  • Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
  • Major surgery < 28 days of first dose
  • Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids; Other inclusion/exclusion criteria may apply
  • All Patients:
  • Primary central nervous system (CNS) tumors

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Which best describes your lung cancer?
  • Has the cancer spread to other parts of the body, or is it too advanced to be removed by surgery?

Where in Taiwan

Also in 12 other countries, 86 sites

  • Kaohsiung Medical University Chung-Ho Memorial HospitalKaohsiung City, TaiwanContact: Revolution MedicinesNo longer taking part
  • Taichung Veterans General HospitalTaichung, TaiwanContact: Revolution MedicinesNo longer taking part
  • Chi Mei Hospital, LiouyingTainan, TaiwanContact: Revolution MedicinesNo longer taking part
  • Taipei Municipal Wanfang HospitalTaipei, TaiwanContact: Revolution MedicinesNo longer taking part
  • Taipei Veterans General HospitalTaipei, TaiwanContact: Revolution MedicinesNo longer taking part

About the trial

What the trial wants to find out

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other.

Read full original descriptionShow less

The first four subprotocols include the following:

Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805

The 4 groups in the trial

  • Subprotocol A: KRAS G12C-Mutated Solid TumorsTreatment being tested

    RMC-6291 (BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W)

    Treatment: RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin, and Pemetrexed

  • Subprotocol B: RAS-mutated NSCLCTreatment being tested

    RMC-6236 (QD) and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W)

    Treatment: RMC-6236, Pembrolizumab, Cisplatin, Carboplatin, and Pemetrexed

  • Subprotocol C: RAS G12D-mutated NSCLCTreatment being tested

    RMC-9805 (QD or BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W).

    Treatment: RMC-6236, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, and RMC-9805

  • Subprotocol D: RAS G12D-mutated NSCLCTreatment being tested

    RMC-9805 (QD)

    Treatment: RMC-9805

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
Plain-language title
Tests RAS(ON) inhibitors in lung cancer with RAS gene mutationsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06162221, who can take part
Record updated
19 October 2026